Central liver toxicity after SBRT: An expanded analysis and predictive nomogram.

[1]  A. Koong,et al.  Assessment of hepatic function decline after stereotactic body radiation therapy for primary liver cancer. , 2017, Practical radiation oncology.

[2]  A. Koong,et al.  Assessment of Hepatic Function Decline After Stereotactic Body Radiation Therapy for Primary Liver Tumors Using the Albumin-Bilirubin (ALBI) Score , 2016 .

[3]  Mary Feng,et al.  Outcomes After Stereotactic Body Radiotherapy or Radiofrequency Ablation for Hepatocellular Carcinoma. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  A. Lamarca,et al.  Impact of biliary stent-related events in patients diagnosed with advanced pancreatobiliary tumours receiving palliative chemotherapy. , 2016, World journal of gastroenterology.

[5]  E. Kunieda,et al.  Phase 2 study of stereotactic body radiotherapy and optional transarterial chemoembolization for solitary hepatocellular carcinoma not amenable to resection and radiofrequency ablation , 2016, Cancer.

[6]  T. Su,et al.  Stereotactic body radiation therapy for small primary or recurrent hepatocellular carcinoma in 132 Chinese patients , 2016, Journal of surgical oncology.

[7]  A. Koong,et al.  Stereotactic body radiation therapy and central liver toxicity: A case report. , 2015, Practical radiation oncology.

[8]  J. Salleron,et al.  Stereotactic body radiation therapy as an ablative treatment for inoperable hepatocellular carcinoma. , 2015, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[9]  Daniel T Chang,et al.  Predictors of toxicity associated with stereotactic body radiation therapy to the central hepatobiliary tract. , 2015, International journal of radiation oncology, biology, physics.

[10]  B. Sangro,et al.  Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  H. Onishi,et al.  Survival outcomes after stereotactic body radiotherapy for 79 Japanese patients with hepatocellular carcinoma , 2015, Journal of radiation research.

[12]  M. Scorsetti,et al.  The challenge of inoperable hepatocellular carcinoma (HCC): results of a single-institutional experience on stereotactic body radiation therapy (SBRT) , 2015, Journal of Cancer Research and Clinical Oncology.

[13]  Sang‐wook Lee,et al.  Radiation-induced liver disease after stereotactic body radiotherapy for small hepatocellular carcinoma: clinical and dose-volumetric parameters , 2013, Radiation oncology.

[14]  Dong Han Lee,et al.  High-dose stereotactic body radiotherapy correlates increased local control and overall survival in patients with inoperable hepatocellular carcinoma , 2013, Radiation oncology.

[15]  A. Koong,et al.  Erratum: Stereotactic body radiotherapy for colorectal liver metastases , 2012 .

[16]  Cynthia S. Johnson,et al.  Stereotactic body radiotherapy for primary hepatocellular carcinoma. , 2011, International journal of radiation oncology, biology, physics.

[17]  E. Jonas,et al.  Covered versus uncovered self- expandable nitinol stents in the palliative treatment of malignant distal biliary obstruction: results from a randomized, multicenter study , 2010, Journal of Digestive Endoscopy.

[18]  A. Koong,et al.  Stereotactic Body Radiotherapy for Colorectal Liver Metastases: A Pooled Analysis , 2010 .

[19]  A. Koong,et al.  Dose-escalation study of single-fraction stereotactic body radiotherapy for liver malignancies. , 2010, International journal of radiation oncology, biology, physics.

[20]  S. Perkins,et al.  Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma , 2010, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

[21]  R. T. Ten Haken,et al.  Radiation-associated liver injury. , 2010, International journal of radiation oncology, biology, physics.

[22]  Don Haeng Lee,et al.  Determination of Diameter and Angulation of the Normal Common Bile Duct using Multidetector Computed Tomography , 2009, Gut and liver.

[23]  L. Gaspar,et al.  Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  E. Pomfret,et al.  Biliary anatomy and embryology. , 2008, The Surgical clinics of North America.

[25]  Maria Hawkins,et al.  Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Hai-jie Lu,et al.  Radiation-induced liver disease in three-dimensional conformal radiation therapy for primary liver carcinoma: the risk factors and hepatic radiation tolerance. , 2006, International journal of radiation oncology, biology, physics.

[27]  Xiao-dong Zhu,et al.  Prediction of radiation-induced liver disease by Lyman normal-tissue complication probability model in three-dimensional conformal radiation therapy for primary liver carcinoma. , 2006, International journal of radiation oncology, biology, physics.

[28]  M. McCarter,et al.  Interim analysis of a prospective phase I/II trial of SBRT for liver metastases , 2006, Acta oncologica.

[29]  Robert D Timmerman,et al.  A phase I trial of stereotactic body radiation therapy (SBRT) for liver metastases. , 2005, International journal of radiation oncology, biology, physics.

[30]  Daniel Normolle,et al.  Analysis of radiation-induced liver disease using the Lyman NTCP model. , 2002, International journal of radiation oncology, biology, physics.

[31]  N. Gourtsoyiannis,et al.  Nitinol Stents for Palliative Treatment of Malignant Obstructive Jaundice: Should We Stent the Sphincter of Oddi in Every Case? , 2001, CardioVascular and Interventional Radiology.

[32]  J. Laméris,et al.  Complications of percutaneously inserted biliary Wallstents. , 1993, Journal of vascular and interventional radiology : JVIR.

[33]  S. Zaman,et al.  Silent cirrhosis in patients with hepatocellular carcinoma. Implications for screening in high‐incidence and low‐incidence areas , 1990, Cancer.

[34]  J. Bruix,et al.  PREVALENCE OF ANTIBODIES TO HEPATITIS C VIRUS IN SPANISH PATIENTS WITH HEPATOCELLULAR CARCINOMA AND HEPATIC CIRRHOSIS , 1989, The Lancet.

[35]  P. Mueller,et al.  Biliary stent endoprosthesis: analysis of complications in 113 patients. , 1985, Radiology.

[36]  Lu-Yu Hwang,et al.  HEPATOCELLULAR CARCINOMA AND HEPATITIS B VIRUS A Prospective Study of 22 707 Men in Taiwan , 1981, The Lancet.

[37]  Merina Ahmed,et al.  Stereotactic body radiotherapy for oligometastases. , 2013, The Lancet. Oncology.

[38]  A. Bilici,et al.  Diameters of the common bile duct in adults and postcholecystectomy patients: a study with 64-slice CT. , 2012, European journal of radiology.

[39]  W. Franklin,et al.  Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.